What does pirfenidone/Axri treat?

Pirfenidone/Pirfenidone is an innovative drug used to treat idiopathic pulmonary fibrosis (IPF). Idiopathic pulmonary fibrosis is a chronic and progressive lung disease in which patients' lung tissue is gradually damaged and replaced by fibrotic scar tissue, leading to symptoms such as difficulty breathing and insufficient oxygen. As an anti-fibrotic drug, the main mechanism of action of pirfenidone is to inhibit the fibrosis process and related inflammatory response in lung tissue, thereby effectively delaying the progression of the disease.

Studies have shown that pirfenidone can significantly slow down the decline of lung function in patients with idiopathic pulmonary fibrosis, improve their quality of life, and may extend the patient's survival time. The results of multiple clinical trials show that patients who use pirfenidone perform better in lung function tests than those who do not use the drug, especially in that the rate of lung function decline is significantly slowed down. The drug not only offers hope for treatment but is also believed to have the potential to improve long-term survival outcomes for patients.

As for the dosage, pirfenidone usually needs to be taken three times a day, with a recommended interval of 12 hours. This medication can be taken with or after meals to help reduce gastrointestinal discomfort that may occur. When taking, patients should swallow the capsules whole and do not chew or crush them. In addition, doctors will regularly monitor patients during their use of pirfenidone to evaluate the effectiveness of the drug and assist patients in controlling possible side effects.

Although pirfenidone has shown good efficacy in the treatment of idiopathic pulmonary fibrosis, like all drugs, it may also cause some side effects, including but not limited to nausea, diarrhea, fatigue, and rash. Therefore, before starting treatment, patients should fully understand the potential risks and benefits of the drug and communicate with their doctor in detail.